You are here

DETECTION OF PRION PROTEIN IN BLOOD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS043884-01
Agency Tracking Number: NS043884
Amount: $123,566.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BIOTECH RESEARCH LABORATORIES 217 PERRY PKY
GAITHERSBURG, MD 20877
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JIUPING JI
 (301) 208-8100
 jji@bbi.com
Business Contact
 MARK MANAK
Phone: (301) 208-8100
Email: MMANAK@BBII.COM
Research Institution
 UNIVERSITY OF MARYLAND
 
UMD
Baltimore, MD 21201
United States

 Nonprofit College or University
Abstract

Prion diseases are 100 percent fatal, there is no treatment available, and cannot be diagnosed prior to the occurrence of symptoms. There is a public health need and an enormous market
for a screening test that can help protect the blood supply, screen live
animals, and ensure food safety. We propose to develop and validate an
innovative, highly sensitive screening method for the detection of the
infectious prion protein in the blood of humans and animals. We have selected
an amplification-boosted analytical method, immuno-polymerase chain reaction
(I-PCR) that utilizes an amplifiable DNA-label coupled to a specific antibody,
and combines serologic and molecular diagnostic potentials to amplify micro
quantities of protein to detectable levels; the method's unparalleled
sensitivity in the sub-femtogram range meets the criterion proposed for
detection of prion in blood. Recombinant phage antibodies will be produced and
used as specific reagents. Preliminary results have shown proof of concept that
IPCR method has the needed sensitivity. The strengths include: (1) a scientific
group with expertise in diagnostics and product development, (2) the selection
of a highly sensitive analytical approach and novel detection probes, and (3) a
strong business partner having expertise in translating prototype assays into
sensitive, specific, and reproducible products.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government